Emphasizing the value of thorough molecular characterization and consideration of additional molecular-targeting approaches for rare subtypes of nccRCC, Pal et al. highlight three case reports of ALK-rearranged RCC having excellent responses to the ALK kinase inhibitor alectinib, even after multiple other lines of other systemic therapies [80]. This evidence concerns the gene ALK and renal cell adenocarcinoma.